GURU.Markets stock price, segment price, and overall market index valuation
The company's share price COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psychedelic therapy (based on psilocybin) for the treatment of depression. Its stock price is a venture capital bet on the legalization and medical use of these substances.
Share prices of companies in the market segment - Pharma psycho
COMPASS Pathways is a company working at the intersection of biotechnology and mental health, developing psilocybin-based therapy for the treatment of treatment-resistant depression. We classify it as "Psychedelic Pharmaceuticals." The chart below illustrates the dynamics of this new and much-discussed segment.
Broad Market Index - GURU.Markets
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for the treatment of treatment-resistant depression. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors view the future of psychedelic medicine.
Change in the price of a company, segment, and market as a whole per day
CMPS - Daily change in the company's share price COMPASS Pathways plc
Shares of COMPASS Pathways, a company researching psychedelics, exhibit extreme volatility, as measured by change_co. This reflects sensitivity to clinical trial results. This metric is important for analyzing the innovative biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma psycho
COMPASS Pathways plc is a biotech company working with psychedelics. This chart highlights the sector's extreme volatility. Comparison with CMPS's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
COMPASS Pathways is a leading company in the psychedelic medicine sector. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization COMPASS Pathways plc
COMPASS Pathways' year-over-year performance reflects the promise and risks associated with psychedelic-based therapies. The company's market capitalization over the past 12 months depends entirely on the results of clinical trials of its psilocybin-based drug for the treatment of depression, as well as changes in the regulatory and societal environment.
Annual dynamics of market capitalization of the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company pioneering the development of psychedelic therapy for the treatment of mental disorders. Its stock price is entirely speculative and based on investor confidence in the future potential of this innovative, yet controversial, approach.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
COMPASS, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects hopes, risks, and legislative changes affecting one of the most controversial areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization COMPASS Pathways plc
The market capitalization of COMPASS, a biopharmaceutical company, is speculative. The monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its psychedelic therapy for depression, a cutting-edge but risky area.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies (the active ingredient in "magic mushrooms") for the treatment of treatment-resistant depression. The chart below shows the overall dynamics of the psychedelic pharmaceutical sector, which is gaining attention as a potentially revolutionary approach to mental health.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of companies developing psychedelic-based therapies are among the most speculative stories in the market. The chart below shows the overall risk appetite. Does COMPASS Pathways move with extreme amplitude, reacting to the slightest changes in investor sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization COMPASS Pathways plc
COMPASS Pathways, a pioneer in developing psilocybin-based therapy for depression, is extremely volatile. Its weekly stock price is reflecting clinical trial results and regulatory changes for psychedelics.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
COMPASS Pathways, like other companies in the psychedelic medicine sector, is riding the wave of general interest in this therapy. Regulatory changes and key research results in the industry are creating a common backdrop. The graph will reveal whether the market perceives CMPS as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
COMPASS Pathways, as a representative of disruptive but currently unprofitable technologies, often amplifies broader market movements. During periods of risk appetite, these companies' shares soar, while during periods of risk aversion, they decline. The chart shows how pronounced this "high-beta" nature is in the shares of this psychedelic medicine company.
Market capitalization of the company, segment and market as a whole
CMPS - Market capitalization of the company COMPASS Pathways plc
The COMPASS Pathways chart is a visual representation of the revolution in mental health treatment. The company is a pioneer in the development of psilocybin-based psychedelic therapy. Its market cap dynamics reflect investors' speculative bet that this radically new approach will gain acceptance and transform psychiatry.
CMPS - Share of the company's market capitalization COMPASS Pathways plc within the market segment - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for the treatment of treatment-resistant depression. Its market capitalization reflects its leadership in the emerging field of psychedelic medicine. The chart below shows volatility associated with clinical and regulatory risks.
Market capitalization of the market segment - Pharma psycho
COMPASS Pathways is a biotech company developing psilocybin-based therapy for treatment-resistant depression. The chart below shows the market capitalization of the psychedelic pharmaceutical sector. Its dynamics reflect a bet on a revolution in psychiatry and the associated risks.
Market capitalization of all companies included in a broad market index - GURU.Markets
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapy (the active component of "magic mushrooms") for the treatment of treatment-resistant depression. The company's market capitalization is a bet on revolutionizing psychiatry. Its market share reflects the potential breakthrough in the treatment of mental disorders using psychedelics.
Book value capitalization of the company, segment and market as a whole
CMPS - Book value capitalization of the company COMPASS Pathways plc
COMPASS Pathways' book value represents capital for a revolution in psychiatry. Its foundation is the intellectual property of synthetic psilocybin (COMP360) and the funds to conduct large-scale clinical trials for the treatment of depression. The chart below shows how the company is accumulating resources to bring psychedelics into mainstream medicine.
CMPS - Share of the company's book capitalization COMPASS Pathways plc within the market segment - Pharma psycho
COMPASS Pathways conducts research on psychedelics for the treatment of mental disorders, relying on its R&D centers. This scientific infrastructure is its key material asset. The S_BCap_Seg chart shows its share of physical assets in the emerging psychopharmacology sector.
Market segment balance sheet capitalization - Pharma psycho
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. COMPASS Pathways, a company developing psychedelic therapies, has a "light" model. Its value lies in its intellectual property and clinical trial data, not in its factories.
Book value of all companies included in the broad market index - GURU.Markets
COMPASS Pathways is a pioneer in developing psilocybin-based therapies for treatment-resistant depression. The company's assets are not factories, but intellectual property and clinical trial data. The chart below illustrates the material weight behind this revolution in psychiatry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - COMPASS Pathways plc
COMPASS Pathways' balance sheet is its patents and psilocybin reserves. The market values it at a colossal premium, seeing it as a leader in the revolutionary field of psychedelic medicine. The chart will show how much the hope for a psychiatric "reboot" outweighs the current asset value.
Market to book capitalization ratio in a market segment - Pharma psycho
COMPASS Pathways plc is a biotech company pioneering the development of psilocybin-based (from mushrooms) therapy for depression. Its value lies in this revolutionary approach. This chart shows how its market valuation, based on enormous expectations, is many times greater than its current assets.
Market to book capitalization ratio for the market as a whole
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapy (from "magic mushrooms") for the treatment of treatment-resistant depression. Its valuation is based on the potential of this revolutionary approach. The chart reflects investor expectations for future changes in psychiatry, not current holdings.
Debts of the company, segment and market as a whole
CMPS - Company debts COMPASS Pathways plc
COMPASS Pathways, a biotech pioneering the development of psilocybin-based therapy for depression, is using raised capital to fund its expensive clinical trials. This chart shows how the company is spending investor funds on research in this new and controversial area of medicine.
Market segment debts - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for the treatment of treatment-resistant depression. This is a cutting-edge, yet regulatoryly challenging, field. This chart shows how the company's debt load reflects its need to fund expensive clinical trials and navigate the complex approval process.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for the treatment of treatment-resistant depression. This is a revolutionary yet controversial field. This chart shows how the company funds its expensive clinical trials in this new and highly regulated field.
Market segment debt to market segment book capitalization - Pharma psycho
COMPASS Pathways, a biotech company developing psychedelic therapies, specifically psilocybin-based, for the treatment of treatment-resistant depression. This chart compares its debt to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its innovative, yet regulatory-challenging, clinical trials.
Debt to book value of all companies in the market
COMPASS Pathways plc is a biotech company pioneering the development of psilocybin-based therapy for treatment-resistant depression. This is a revolutionary yet controversial field. This chart of total market debt shows risk appetite, which is important for assessing the company's ability to fund its expensive clinical trials.
P/E of the company, segment and market as a whole
P/E - COMPASS Pathways plc
This chart for COMPASS Pathways, a biotech pioneer in developing psilocybin therapy for treatment-resistant depression, illustrates the high valuation of its innovative approach. There is no profit. The metric reflects investors' high hopes that psychedelics will become a new class of drugs for treating mental disorders.
P/E of the market segment - Pharma psycho
COMPASS Pathways is a biotech company developing psychedelic therapies, specifically psilocybin, for the treatment of treatment-resistant depression. This chart illustrates the average valuation in the psychopharmaceutical sector, where investors are betting on breakthrough approaches to treating mental disorders despite regulatory and societal barriers.
P/E of the market as a whole
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapy (from "magic mushrooms") for the treatment of treatment-resistant depression. This chart shows the overall risk appetite. Comparison helps understand whether the company is viewed as a leader in a revolution in psychiatry or a risky project dependent on regulatory decisions and public opinion.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company COMPASS Pathways plc
This chart from COMPASS Pathways, a company developing psychedelic-based therapies for mental disorders, shows market expectations for its clinical trials. It reflects investor confidence in the revolutionary potential of its approach and the future commercialization of this new class of treatments.
%20P%2FE%20COMPASS%20Pathways%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-COMPASS-Pathways-plc&v=1772513423498 "Chart of the company's future (projected) P/E COMPASS Pathways plc")
Future (projected) P/E of the market segment - Pharma psycho
COMPASS Pathways plc is a company developing psychedelic therapies, specifically psilocybin, for the treatment of mental disorders. This chart shows average expectations for the biotech sector. The CMPS position may indicate how much investors believe in the potential of this new treatment approach and its ability to overcome regulatory barriers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772513423507 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
COMPASS Pathways is a biotech company researching psilocybin for the treatment of mental disorders. This is a disruptive and risky field. The overall market optimism evident in this chart is critical to attracting investment in such innovative, yet unproven, approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513423512 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit COMPASS Pathways plc
COMPASS Pathways plc is a biotech company developing psilocybin-based therapy (the active ingredient in "magic mushrooms") for the treatment of treatment-resistant depression. This chart reflects their revolutionary approach to mental health. The losses represent clinical trial costs, while the potential profit explosion depends on the approval of their groundbreaking treatment.
Profit of companies in the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company pioneering the development of psychedelic therapies, particularly psilocybin, for the treatment of depression. Profitability in this sector, as this chart shows, is a bet on a paradigm shift in psychiatry. CMPS's success depends on the results of clinical trials and changes in regulatory and public attitudes toward such treatments.
Overall market profit
COMPASS Pathways, a biotech company researching psychedelics for the treatment of mental disorders, is a pioneer in a new field of medicine. Its success depends entirely on the results of clinical trials and regulatory changes. The economic cycles visible in this graph do not affect the need for depression treatment, but they do affect the availability of capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company COMPASS Pathways plc
COMPASS Pathways is a pioneer in developing psilocybin-based therapies for treatment-resistant depression. This chart reflects analysts' forecasts, which are a bet on the success of its clinical programs and the potential paradigm shift in mental health treatment.
%20profit%20of%20the%20company%20COMPASS%20Pathways%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-COMPASS-Pathways-plc&v=1772513423565 "Graph of future (projected) profit of the company COMPASS Pathways plc")
Future (predicted) profit of companies in the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company developing psilocybin-based therapy (a component of "magic mushrooms") for the treatment of treatment-resistant depression. This is a cutting-edge and revolutionary approach to psychiatry. This chart shows the profit forecast for the psychopharmaceutical sector, reflecting expectations for the legalization and acceptance of psychedelic therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772513423591 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
COMPASS Pathways is a biotech company researching psilocybin (a component of hallucinogenic mushrooms) for the treatment of depression. Its success depends solely on the results of clinical trials and regulatory decisions. The overall economic outlook influences it only indirectly, through investor sentiment and their willingness to fund innovative but risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513423606 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies (the active ingredient in "magic mushrooms") for the treatment of treatment-resistant depression. It has no commercial revenue. The chart reflects investors' belief in the revolutionary potential of psychedelics for psychiatry and its leadership in this emerging field.
P/S market segment - Pharma psycho
COMPASS Pathways is a biotech company developing psilocybin-based therapies for the treatment of treatment-resistant depression. The chart shows the average revenue estimate for the biotech industry. It allows one to estimate the premium investors are placing on the company for its leadership in the resurgent field of psychedelic medicine.
P/S of the market as a whole
COMPASS Pathways plc is a pioneer in developing psychedelic-based therapies for the treatment of mental disorders, particularly treatment-resistant depression. This is a revolutionary approach. A chart of average market revenue estimates shows that investors are buying not revenue, but the potential for a paradigm shift in psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapy for the treatment of treatment-resistant depression. The chart reflects the valuation of this new approach to mental health. The value is based on projected future revenues that could be generated if its innovative therapy is approved.
%20P%2FS%20COMPASS%20Pathways%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-COMPASS-Pathways-plc&v=1772513423659 "The graph of the company's future (projected) P/S COMPASS Pathways plc")
Future (projected) P/S of the market segment - Pharma psycho
COMPASS Pathways plc is a biotechnology company developing psilocybin-based therapies for the treatment of treatment-resistant depression. This figure reflects the average future sales estimate for companies in the psychedelic pharmaceuticals sector. This provides an indication of how highly the market values COMPASS's innovative approach and its potential in the emerging mental health market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772513423677 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
COMPASS Pathways is a pioneer in developing psychedelic-based therapies for mental disorders. This approach is revolutionary. This graph of overall revenue expectations is irrelevant. The entire value of CMPS lies in the success of clinical trials and the changing regulatory landscape for this new class of drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513423715 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psychedelic therapies, specifically psilocybin, for the treatment of mental disorders. Currently in clinical trials, it has no sales revenue. This graph shows future revenue following the potential approval and commercialization of its innovative treatments.
Sales of companies in the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company at the forefront of mental health research. It is developing a therapeutic agent based on psilocybin (the active component of "magic mushrooms") for the treatment of treatment-resistant depression. This chart shows the sector's total revenue, reflecting the growing interest in psychedelic medicine.
Overall market sales
COMPASS Pathways plc is a biotech company developing psilocybin-based therapy for the treatment of treatment-resistant depression. This chart reflects the state of the economy, but CMPS is at the forefront of a revolution in psychiatry. Its success depends on the results of clinical trials and changing regulatory attitudes toward psychedelic medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for treatment-resistant depression. Its future hinges on the success of clinical trials and changing regulatory attitudes. This timeline reflects the enormous, albeit risky, expectations of this new era in psychiatry.
%20sales%20of%20the%20company%20COMPASS%20Pathways%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-COMPASS-Pathways-plc&v=1772513423728 "Schedule of future (projected) sales of the company COMPASS Pathways plc")
Future (projected) sales of companies in the market segment - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapy (the active ingredient in "magic mushrooms") for the treatment of treatment-resistant depression. The chart shows forecasts for the psychopharmacology sector. This is a revolutionary approach, and the company's success depends on the results of clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772513423733 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
COMPASS Pathways is a biotech company researching psilocybin (a component of "magic mushrooms") for the treatment of treatment-resistant depression. Its success depends on clinical trial results and changes in the regulatory environment. This chart, reflecting overall investor sentiment, affects the availability of capital for such cutting-edge, yet risky, medical advances.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513423738 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality COMPASS Pathways plc
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for treatment-resistant depression. This is a cutting-edge field of science with significant research investment. This chart illustrates the investment in developing a new class of drugs that could transform psychiatry and generate profits.
Market segment marginality - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for treatment-resistant depression. This chart shows the average profitability in the pharmaceutical industry. The breakthrough nature of its research and the potential to create a new class of mental health medications could lead to exceptionally high profitability.
Market marginality as a whole
COMPASS Pathways plc is a biotech company developing psilocybin-based therapies for the treatment of treatment-resistant depression. This is a cutting-edge and regulatoryly complex field. This total profit chart vividly illustrates the contrast between traditional businesses and companies working at the intersection of medicine and changing public perceptions of psychedelics.
Employees in the company, segment and market as a whole
Number of employees in the company COMPASS Pathways plc
COMPASS Pathways is developing psilocybin-based therapeutics. Its team includes scientists, clinical trial managers, and therapists. This schedule represents an investment in the unique specialists needed to navigate new clinical and regulatory pathways for psychedelic medicine.
Share of the company's employees COMPASS Pathways plc within the market segment - Pharma psycho
COMPASS Pathways is a biotech company pioneering the development of psilocybin-based therapies for the treatment of treatment-resistant depression. It is at the forefront of psychiatry. This chart shows the proportion of unique specialists (psychiatrists, neuroscientists, clinicians) in this new and controversial field that COMPASS attracts, reflecting its leadership and scientific weight.
Number of employees in the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company pioneering the development of psychedelic therapies, specifically psilocybin, for the treatment of treatment-resistant depression. The growth of its scientific and clinical team, visible in the graph, reflects progress in this innovative field. This increase is due to the ongoing implementation of large-scale clinical trials.
Number of employees in the market as a whole
COMPASS Pathways plc is a biotech company developing psychedelic therapies for the treatment of mental disorders. Its business is at the forefront of medicine and is not dependent on the economic cycles shown in this chart. The company's value is determined by scientific progress and changes in the regulatory environment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company COMPASS Pathways plc (CMPS)
COMPASS Pathways is a pioneer in psychedelic therapy. Its market cap is a bet on revolutionizing the treatment of mental disorders. This chart shows the extremely high valuation of its intellectual property and clinical research data, which are being generated by a small team of visionaries and scientists.
%20of%20the%20company%20COMPASS%20Pathways%20plc%20(CMPS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-COMPASS-Pathways-plc-CMPS&v=1772513423825 "Chart of market capitalization per employee (in thousands of dollars) of the company COMPASS Pathways plc (CMPS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
COMPASS Pathways plc is a biotech company developing psilocybin-based therapies for the treatment of treatment-resistant depression. This is a cutting-edge field where all the value is concentrated in clinical trials. This chart shows how highly investors value the potential of their innovative approach per researcher.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772513423834 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
COMPASS Pathways is a company developing psychedelic therapies, specifically psilocybin, for the treatment of treatment-resistant depression. The chart reflects the valuation of this breakthrough idea in medicine. The very high market capitalization per employee demonstrates investors' belief in the potential to change the paradigm of mental health treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513423843 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company COMPASS Pathways plc (CMPS)
COMPASS Pathways is a biotech company working at the intersection of psychedelics and psychiatry. They are developing psilocybin-based therapy for depression. This is a cutting-edge and controversial field. This chart shows the cost of this R&D. It measures how much capital is burned per scientist conducting clinical trials.
%20Chart%20COMPASS%20Pathways%20plc%20(CMPS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-COMPASS-Pathways-plc-CMPS&v=1772513423851 "Company Profit Per Employee (in thousands of dollars) Chart COMPASS Pathways plc (CMPS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
COMPASS Pathways (CMPS) is a biotech R&D company (psychedelics for depression). This chart shows the benchmark for "Psycho-Pharma" (R&D). The average profit per employee in this sector is *negative*. This benchmark reflects cash burn: the sector spends millions on R&D (clinical trials) in hopes of a future breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772513423857 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
COMPASS Pathways (CMPS) is a biotech company pioneering the development of psilocybin (from "magic mushrooms") therapy for treatment-resistant depression. It is an R&D company. This graph shows the loss per employee, as all resources are invested in clinical trials and the creation of a new paradigm in psychiatry.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513423866 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee COMPASS Pathways plc (CMPS)
COMPASS Pathways is a biotech company developing psilocybin-based therapies for depression. This graph will reflect progress in commercialization. Achieving and increasing revenue per employee will signal recognition of its innovative approach, potentially through partnerships with major pharma.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-COMPASS-Pathways-plc-CMPS&v=1772513423871 "Sales chart per company employee COMPASS Pathways plc (CMPS)")
Sales per employee in the market segment - Pharma psycho
COMPASS Pathways (CMPS) is a biotech company at the forefront of psychedelic research (psilocybin) for the treatment of treatment-resistant depression. It is an R&D company. This chart does not reflect its value. CMPS has no commercial revenue. Employee productivity is measured not by sales, but by progress in clinical trials.
Sales per employee for the market as a whole
COMPASS Pathways is a biotech company working in the mental health field, specifically with psilocybin. They are deep in R&D and clinical trials. At this stage, this metric is low, reflecting their investment in science. This metric will become key if their therapy is approved and demonstrates commercial viability.
Short shares by company, segment and market as a whole
Shares shorted by company COMPASS Pathways plc (CMPS)
COMPASS Pathways (CMPS) is a biotech company leading the "psychedelic revolution" in medicine. They are developing a psilocybin-based therapy (from mushrooms) for the treatment of severe depression. This indicator measures skepticism. "Bears" doubt the success of clinical trials or the approval of this therapy by regulators and the public.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-COMPASS-Pathways-plc-CMPS&v=1772513423911 "Short Shares Chart for the Company COMPASS Pathways plc (CMPS)")
Shares shorted by market segment - Pharma psycho
COMPASS Pathways (CMPS) is a leading company in the psychedelic medicine sector, developing psilocybin (mushroom)-based therapy for depression. This chart shows the bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism about the legalization and commercialization of psychedelics.
Shares shorted by the overall market
COMPASS Pathways is a leader in the speculative development of psychedelics for the treatment of depression. It's a business built on future expectations. When this market fear indicator rises, a "venture winter" freezes the sector. Investors panic and flee unprofitable biotechs, and "dream" stocks like CMPS are the first to sell off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator COMPASS Pathways plc (CMPS)
COMPASS Pathways (CMPS) is a biotech company leading the development of psychedelic therapeutics. Their lead candidate is synthetic psilocybin (a component of mushrooms) for the treatment of treatment-resistant depression. This chart measures hype. It shows "overheated" (above 70) due to positive trial data or "oversold" (below 30) amid regulatory delays in this emerging field.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-COMPASS-Pathways-plc-CMPS&v=1772513423942 "RSI 14 indicator chart for the company's stock COMPASS Pathways plc (CMPS)")
RSI 14 Market Segment - Pharma psycho
COMPASS Pathways (CMPS) is a biotech leader developing psilocybin-based (from mushrooms) therapies for treatment-resistant depression. This is a highly speculative industry. This chart tracks the collective hype in the Psychedelics sector. It shows when the entire industry is overheated by speculative hype or oversold by regulatory news.
RSI 14 for the overall market
For COMPASS Pathways, which develops psychedelic therapy, this chart is an indicator of risk appetite. During periods of euphoria, investors are willing to "buy the dream" and fund the most speculative R&D projects. In moments of panic, capital flees "concepts" first, and CMPS risks running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CMPS (COMPASS Pathways plc)
COMPASS Pathways (CMPS) is a biotech company leading the development of psilocybin-based therapies (from "magic mushrooms") for the treatment of treatment-resistant depression. This chart displays the average price target. It reflects analysts' assessments of the clinical trial data, regulatory hurdles, and commercial potential of psychedelic medicine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CMPS-COMPASS-Pathways-plc&v=1772513423969 "A chart showing analyst consensus forecasts for the expected stock price. CMPS (COMPASS Pathways plc)")
The difference between the consensus estimate and the actual stock price CMPS (COMPASS Pathways plc)
COMPASS Pathways is a biotech pioneer leading the race to bring psilocybin (a compound found in magic mushrooms) to market as an approved treatment for depression. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. It reflects their view on this revolutionary yet risky field.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CMPS-COMPASS-Pathways-plc&v=1772513423973 "A chart showing the difference between the consensus forecast and the actual stock price. CMPS (COMPASS Pathways plc)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
COMPASS Pathways (CMPS) is a pioneer in psychedelic medicine. The company is conducting clinical trials of its patented form of psilocybin (mushrooms) for the treatment of depression. This chart shows general expectations for the pharmaceutical sector, reflecting whether experts believe psychedelics have a medical future.
Analysts' consensus forecast for the overall market share price
COMPASS Pathways (CMPS) is a leader in R&D for psychedelics (psilocybin) for depression. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index COMPASS Pathways plc
COMPASS Pathways is a flagship company in psychedelic medicine. They are a leader in the development of synthetic psilocybin (a substance found in magic mushrooms) for the treatment of treatment-resistant depression. This chart represents the entire industry, reflecting their progress in clinical trials and the market's belief that psilocybin therapy will become a legal and approved medicine.
AKIMA Market Segment Index - Pharma psycho
COMPASS (CMPS) is a leader in the psychedelic revolution (like Atai); the company (backed by Peter Thiel) is in the final stages of developing its proprietary psilocybin formula (COMP360) for the treatment of treatment-resistant depression. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this futuristic (R&D) bet (CMPS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Compass Pathways is a mental health company developing psilocybin therapy (COMP360) for the treatment of depression. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to the adoption and funding of psychedelic medicine.
